Silk Road Medical
Founded Year
2007Stage
IPO | IPOTotal Raised
$160.6MDate of IPO
4/4/2019Market Cap
0.38BStock Price
9.73About Silk Road Medical
Silk Road Medical (Nasdaq: SILK) operates as a medical device company. It develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary trans-carotid therapies. The company improves the lives of people with carotid artery disease by focusing on proven surgical principles and developing technology for vascular specialists. The company was founded in 2007 and is based in Sunnyvale, California.
Loading...
Loading...
Silk Road Medical Patents
Silk Road Medical has filed 115 patents.
The 3 most popular patent topics include:
- vascular diseases
- arteries of the head and neck
- stroke
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/9/2020 | 9/19/2023 | Transcription factors, Arteries of the head and neck, Vascular diseases, Angiology, Neurological disorders | Grant |
Application Date | 11/9/2020 |
|---|---|
Grant Date | 9/19/2023 |
Title | |
Related Topics | Transcription factors, Arteries of the head and neck, Vascular diseases, Angiology, Neurological disorders |
Status | Grant |
Latest Silk Road Medical News
Nov 17, 2023
New York, New York--(Newsfile Corp. - November 17, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ: SILK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Silk Road and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On October 10, 2023, Silk Road announced that its second quarter 2023 revenues were expected to be below its first quarter revenues and significantly reduced its expected full year 2023 revenues. Concurrently, Silk Road announced the departure of Chief Executive Officer Erica Rogers. Although Silk Road did not offer any explanation for its reduced revenues, the announcement followed the Centers for Medicare & Medicaid Services' July 2023 proposed National Coverage Determination, which reportedly proposed to change coverage for a stroke treatment for carotid artery disease that could put a competing therapy alongside Silk Road's Transcarotid Artery Revascularization therapy regarding reimbursement. On this news, Silk Road's stock price fell $6.86 per share, or 49.04%, to close at $7.13 per share on October 11, 2023. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:
Silk Road Medical Frequently Asked Questions (FAQ)
When was Silk Road Medical founded?
Silk Road Medical was founded in 2007.
Where is Silk Road Medical's headquarters?
Silk Road Medical's headquarters is located at 735 Pastoria Avenue, Sunnyvale.
What is Silk Road Medical's latest funding round?
Silk Road Medical's latest funding round is IPO.
How much did Silk Road Medical raise?
Silk Road Medical raised a total of $160.6M.
Who are the investors of Silk Road Medical?
Investors of Silk Road Medical include Warburg Pincus, The Vertical Group, CRG, Norwest Venture Partners and Janus Capital Group.
Who are Silk Road Medical's competitors?
Competitors of Silk Road Medical include Bioheart.
Loading...
Compare Silk Road Medical to Competitors
Quasar specializes in the manufacturing of products for the medical device market. It provides rapid prototyping, sensor development, assembly solutions, and components and device manufacturing. The company offers its services to the medical device industry. It was founded in 1988 and is based in Yokneam Illit, Israel.
SMT develops and manufactures cardiac products in India. Its product portfolio includes coronary stents (drug-eluting and bare-metal), renal stents, angioplasty balloon catheters, and other cardiac accessories in India and abroad. SMT was founded in 1998 and is based in Surat, India.
Translumina is a global Interventional cardiovascular devices company. Translumina is a fully integrated product development and manufacturing company with manufacturing facilities in Germany and India. The company commercializes products in over 50 countries globally through 2 distinct business entities, International and India.
Shanghai Kinetic (300326.SZ) is a medical device manufacturer for multidisciplinary specialties including Orthopedics, Cardiovascular and Sports Medicine.
BridgePoint Medical is focused on developing technology in the field of interventional cardiology for access to and treatment of chronic total occlusions. In September 2012, BridgePoint medical was acquired by Boston Scientific. The valuation of BridgePoint Medical was undisclosed. Other terms of the deal were not released.
Lepu Medical (SHE:300003) is specialized in developing, manufacturing, and marketing medical devices and equipment. It manufactures devices that serve in the fields of cardiovascular interventions, structural heart diseases, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics and general surgery with products include coronary stents, dilatation balloon catheters, interventional accessories, occlusion devices, mechanical heart valves, electrophysiology catheters, pacemakers. The company was founded in 1999 and is based in Bejing, China.
Loading...